Research has not yet evaluated whether myo-inositol can balance hormones in healthy people without PCOS or fertility issues.

Myo-inositol—typically given at 2–4 g daily in combination with 200–400 μg folic acid—has been shown to improve ovarian parameters in women with polycystic ovary syndrome. In non‐PCOS women undergoing in vitro fertilization, one study reported that myo-inositol reduced gonadotropin requirements (2,084 ± 648 IU versus 2,479 ± 979 IU, p < 0.05) and modified luteinizing hormone levels (2.7 ± 1.1 vs. 1.6 ± 0.9, p < 0.01) while yielding fewer oocytes (5.9 ± 2.4 vs. 7.6 ± 3.8, p < 0.01) and producing no significant differences in pregnancy or implantation rates. No study has evaluated hormone balancing effects in healthy, non-infertile populations outside of the assisted reproduction setting. Mild gastrointestinal side effects have been noted at higher doses, although no substantial safety concerns were reported.

Myo-Inositol for Hormonal Balance – Report

References

Lisi, F., Carfagna, P., Oliva, M., Rago, R., Lisi, R., Poverini, R., Manna, C., Vaquero, E., Caserta, D., Raparelli, V., Marci, R., & Moscarini, M. (2012). Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reproductive Biology and Endocrinology, 10(1), 52. https://doi.org/10.1186/1477-7827-10-52

Laganà, A. S., Vitagliano, A., Noventa, M., Ambrosini, G., & D’Anna, R. (2018). Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Archives of Gynecology and Obstetrics, 298(4), 675–684. https://doi.org/10.1007/s00404-018-4861-y

Sortino, M. A., Salomone, S., Carruba, M. O., & Drago, F. (2017). Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Frontiers in Pharmacology, 8. https://doi.org/10.3389/fphar.2017.00341

Gerli, S., Papaleo, E., Ferrari, A., & Renzo, G. D. (2007). Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences.

F. R. C. “Computer S., Academy, I. S. M., V.I. Kulakov Research Center of Obstetrics, G. and P., & Academy, I. S. M. (2018). Myo-inositol: micronutrient for “fine tuning” of the female reproductive sphere. LLC Russian Medical Journal. https://doi.org/10.32364/2618-8430-2018-1-2-148-155